Browsing by Author "Yalcinkaya, F"

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    Effects of nutritional vitamin D supplementation on markers of bone and mineral metabolism in children with chronic kidney disease
    Lerch, C; Shroff, R; Wan, M; Rees, L; Aitkenhead, H; Bulut, IK; Thurn, D; Bayazit, AK; Niemirska, A; Canpolat, N; Duzova, A; Azukaitis, K; Yilmaz, E; Yalcinkaya, F; Harambat, J; Kiyak, A; Alpay, H; Habbig, S; Zaloszyc, A; Soylemezoglu, O; Candan, C; Rosales, A; Melk, A; Querfeld, U; Leifheit-Nestler, M; Sander, A; Schaefer, F; Haffner, D; Cortina, G; Arbeiter, K; Dusek, J; Harambat, J; Ranchin, B; Fischbach, M; Zalosczyk, A; Querfeld, U; Habbig, S; Galiano, M; Büscher, R; Gimpel, C; Kemper, M; Melk, A; Thurn, D; Schaefer, F; Doyon, A; Wühl, E; Pohl, M; Wygoda, S; Jeck, N; Kranz, B; Wigger, M; Montini, G; Lugani, F; Testa, S; Vidal, E; Matteucci, C; Picca, S; Jankauskiene, A; Azukaitis, K; Zurowska, A; Drodz, D; Tkaczyk, M; Urasinski, T; Litwin, M; Niemirska, A; Szczepanska, M; Texeira, A; Peco-Antic, A; Bucher, B; Laube, G; Anarat, A; Bayazit, AK; Yalcinkaya, F; Basin, E; Cakar, N; Soylemezoglu, O; Duzova, A; Bilginer, Y; Erdogan, H; Donmez, O; Balat, A; Kiyak, A; Caliskan, S; Canpolat, N; Candan, C; Civilibal, M; Emre, S; Alpay, H; Ozcelik, G; Mir, S; Sözeri, B; Yavascan, O; Tabel, Y; Ertan, P; Yilmaz, E; Shroff, R; Prytula, A; Bachetta, J; Haffner, D; Klaus, G; Gessner, M; Schmitt, CP; Stabouli, S; Reusz, G; Verrina, E; Groothoff, J; Tondel, C; Gamero, MA; Petrosyan, E; Bakkaloglu, SA; Dursun, I; Shroff, R
    Background. We investigated the effects of nutritional vitamin D supplementation on markers of bone and mineral metabolism, i.e. serum levels of fibroblast growth factor 23 (FGF23), Klotho, bone alkaline phosphatase (BAP) and sclerostin, in two cohorts with chronic kidney disease (CKD). Methods. In all, 80 vitamin D-deficient children were selected: 40 with mild to moderate CKD from the ERGO study, a randomized trial of ergocalciferol supplementation [ estimated glomerular filtration rate (eGFR) 55 mL/min/1.73 m(2)], and 40 with advanced CKD from the observational Cardiovascular Comorbidity in Children with Chronic Kidney Disease (4C) study (eGFR 24 mL/min/1.73 m2). In each study, vitamin D supplementation was started in 20 children and 20 matched children not receiving vitamin D served as controls. Measures were taken at baseline and after a median period of 8 months. Age- and gender-related standard deviation scores (SDSs) were calculated. Results. Before vitamin D supplementation, children in the ERGO study had normal FGF23 (median 0.31 SDS) and BAP (-0.10 SDS) but decreased Klotho and sclerostin (-0.77 and -1.04 SDS, respectively), whereas 4C patients had increased FGF23 (3.87 SDS), BAP (0.78 SDS) and sclerostin (0.76 SDS) but normal Klotho (-0.27 SDS) levels. Vitamin D supplementation further increased FGF23 in 4C but not in ERGO patients. Serum Klotho and sclerostin normalized with vitamin D supplementation in ERGO but remained unchanged in 4C patients. BAP levels were unchanged in all patients. In the total cohort, significant effects of vitamin D supplementation were noted for Klotho at eGFR 40-70 mL/min/1.73 m(2). Conclusions. Vitamin D supplementation normalized Klotho and sclerostin in children with mild to moderate CKD but further increased FGF23 in advanced CKD.
  • No Thumbnail Available
    Item
    Low levels of urinary epidermal growth factor predict chronic kidney disease progression in children
    Azukaitis, K; Ju, WJ; Kirchner, M; Nair, V; Smith, M; Fang, ZY; Thurn-Valsassina, D; Bayazit, A; Niemirska, A; Canpolat, N; Bulut, IK; Yalcinkaya, F; Paripovic, D; Harambat, J; Cakar, N; Alpay, H; Lugani, F; Mencarelli, F; Civilibal, M; Erdogan, H; Gellermann, J; Vidal, E; Tabel, Y; Gimpel, C; Ertan, P; Yavascan, O; Melk, A; Querfeld, U; Wühl, E; Kretzler, M; Schaefer, F; Arbeiter, K; Rosales, A; Dusek, J; Zaloszyc, A; Liebau, M; Weber, L; Muschiol, E; Büscher, R; Oh, J; Thurn-Valassina, D; Haffner, D; John, U; Wygoda, S; Jeck, N; Wigger, M; Testa, S; Murer, L; Matteucci, C; Jankauskiene, A; Drozdz, D; Zurowska, A; Zaniew, M; Litwin, M; Nimierska, A; Teixeira, A; Peco-Antic, A; Laube, G; Anarat, A; Duzova, A; Bilginer, Y; Caliskan, S; Mir, S; Sozeri, B; Kranz, B; Dorn, B; Baskin, E; Soylemezoglu, O; Emre, S; Candan, C; Kiyak, A; Ozcelik, G; Shroff, R; Rachin, B; Szczepanska, M; Donmez, O; Balat, A; Aksu, N; Yilmaz, E; Anarat, A; Bakkaloglu, A; Ozaltin, F; Peco-Antic, A; Sallay, P; Drozdz, D; Bonzel, KE; Wingen, AM; Urowska, AZ; Balasz, I; Trivelli, A; Perfumo, F; Müller-Wiefel, DE; Möller, K; Offner, G; Enke, B; Hadtstein, C; Mehls, O; Emre, S; Caliskan, S; Mir, S; Wygoda, S; Hohbach-Hohenfellner, K; Jeck, N; Klaus, G; Ardissino, G; Testa, S; Montini, G; Charbit, M; Niaudet, P; Afonso, AC; Fernandes-Teixeira, A; Dusek, J; Matteucci, C; Picca, S; Wigger, M; Berg, UB; Celsi, G; Fischbach, M; Terzic, J; Fydryk, J; Urasinski, T; Coppo, R; Peruzzi, L; Grenda, R; Neuhaus, TJ
    Urinary epidermal growth factor (uEGF) has recently been identified as a promising biomarker of chronic kidney disease (CKD) progression in adults with glomerular disease. Low levels of uEGF predict CKD progression and appear to reflect the extent of tubulointerstitial damage. We investigated the relevance of uEGF in pediatric CKD. We performed a post hoc analysis of the Cardiovascular Comorbidity in Children with CKD (4C) study, which prospectively follows children aged 6-17 years with baseline estimated glomerular filtration rate (eGFR) of 10-60 ml/min/1.73 m(2). uEGF levels were measured in archived urine collected within 6 months of enrollment. Congenital abnormalities of the kidney and urinary tract were the most common cause of CKD, with glomerular diseases accounting for <10% of cases. Median eGFR at baseline was 28 ml/min/1.73 m(2), and 288 of 623 participants (46.3%) reached the composite endpoint of CKD progression (50% eGFR loss, eGFR < 10 ml/min/1.73 m(2), or initiation of renal replacement therapy). In a Cox proportional hazards model, higher uEGF/Cr was associated with a decreased risk of CKD progression (HR 0.76; 95% CI 0.69-0.84) independent of age, sex, baseline eGFR, primary kidney disease, proteinuria, and systolic blood pressure. The addition of uEGF/Cr to a model containing these variables resulted in a significant improvement in C-statistics, indicating better prediction of the 1-, 2- and 3-year risk of CKD progression. External validation in a prospective cohort of 222 children with CKD demonstrated comparable results. Thus, uEGF may be a useful biomarker to predict CKD progression in children with CKD.
  • No Thumbnail Available
    Item
    Reno-vascular hypertension in childhood: a nationwide survey
    Bayazit, AK; Yalcinkaya, F; Cakar, N; Duzova, A; Bircan, Z; Bakkaloglu, A; Canpolat, N; Kara, N; Sirin, A; Ekim, M; Oner, A; Akman, S; Mir, S; Baskin, E; Poyrazoglu, HM; Noyan, A; Akil, I; Bakkaloglu, S; Soylu, A
    Renovascular disease accounts for 8-10% of all cases of paediatric hypertension, whereas, in adults, its incidence is approximately 1%. The Turkish Paediatric Hypertension Group aimed to create the first registry database for childhood renovascular hypertension in Turkey. Twenty of the 28 paediatric nephrology centres in Turkey responded to the survey and reported 45 patients (27 girls, 18 boys) with renovascular hypertension between 1990 and 2005. The age at presentation ranged from 20 days to 17 years. The mean blood pressure at the diagnosis was 169/110 mmHg. Chief complaints of symptomatic patients were headache (38%), seizure (18%), epistaxis (4%), growth retardation (4%), cognitive dysfunction (4%), polyuria (2%), palpitation (2%), and hemiplegia (2%). Renovascular hypertension was found incidentally in 11 children. The diagnosis of renovascular hypertension was established with conventional angiography in 39 patients, MR angiography in three, CT angiography in two, and captopril diethylene triamine penta-acetic acid (DTPA) scintigraphy in one patient. Twenty-one children had bilateral renal artery stenosis and 24 had unilateral renal artery stenosis. Of these, 14 (31%) had fibromuscular dysplasia; 12 (27%) Takayasu's arteritis; six (13%) neurofibromatosis; two (5%) Williams syndrome; one (2%) Kawasaki disease; one (2%) mid-aortic syndrome; one (2%) extrinsic compression to the renal artery, and eight (18%) unspecified bilateral renal artery stenosis. Hypertension was controlled with antihypertensive drugs in 17 patients. Percutaneous transluminal angioplasty (PTRA) or surgery had to be performed in 28 patients: PTRA in 16 patients, PTRA + surgery in one patient and surgery in 11 patients (four nephrectomies). The importance of vasculitic disease, especially Takayasu's arteritis, should not be underestimated in children with renovascular hypertension.
  • No Thumbnail Available
    Item
    Renovascular hypertension in childhood: A nation-wide survey
    Bayazit, AK; Yalcinkaya, F; Cakar, N; Duzova, A; Bircan, Z; Aslan, S; Bakkaloglu, A; Canpolat, N; Kara, N; Sirin, A; Ekim, M; Oner, A; Akman, S; Mir, S; Baskin, E; Poyrazoglu, H; Noyan, A; Akil, I; Bakkaloglu, S; Soylu, A
  • No Thumbnail Available
    Item
    URINARY EPIDERMAL GROWTH FACTOR (UEGF) IMPROVES PREDICTION OF CHRONIC KIDNEY DISEASE (CKD) PROGRESSION IN CHILDREN
    Azukaitis, K; Ju, WJ; Kirchner, M; Smith, M; Nair, V; Fang, ZY; Thurn-valsassina, D; Bayazit, A; Niemirska, A; Canpolat, N; Bulut, IK; Yalcinkaya, F; Paripovic, D; Harambat, J; Cakar, N; Alpay, H; Lugani, F; Mencarelli, F; Civilibal, M; Erdogan, H; Gellermann, J; Vidal, E; Tabel, Y; Gimpel, C; Ertan, P; Yavascan, O; Melk, A; Querfeld, U; Kretzler, M; Schaefer, F